The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Economic aspects of bladder cancer: what are the benefits and costs?
Open accessAbstract
OBJECTIVE: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate and ongoing invasive monitoring requirement are the key contributors to the economic and human toll of this disease. The purpose of this paper was to utilize the recent literature to identify opportunities for improving the benefits and costs of BC care. METHODS: A PubMed search was performed of recent publications concerning (BC) cost-effectiveness. We reviewed studies, reviews, opinion papers and cost-effectiveness analyses, focusing primarily on non-muscle-invasive bladder cancer (Ta/T1; NMIBC). RESULTS: New diagnostic tools such as urine markers may assist in more cost-effectively detecting BC at an earlier stage, however, these markers cannot replace the cystoscopy, which is the current standard of care. A photodynamic diagnostic tool (PDD) using hexylaminolevulinate (Hexvix) enhances tumor visibility and improves transurethral resection of bladder cancer (TURB) results, potentially reducing recurrence rates and lowering treatment costs. While the importance of BC research has been acknowledged, research investment has been continuously reduced during the last 5 years. CONCLUSIONS: The economic burden of BC is well-characterized in the literature. This study suggests that new technologies (i.e., urine-based tests, PDD) and therapeutic regimes (intravesical chemotherapy, adjuvant immunotherapy) have significant potential to improve the diagnosis, treatment and on-going monitoring of BC patients, with potential improvements in clinical outcomes and concurrent cost-savings. A renewed interest and investment in BC research are required to ensure future advancements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
The health economics of bladder cancer: A comprehensive review of the published literature
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003) · PharmacoEconomics · doi:10.1007/bf03262330 · Cited by 860
SYLVESTER, R. J., OOSTERLINCK, W., & van der MEIJDEN, A. P. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000125486.92260.b2 · Cited by 743
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., & Palou-Redorta, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.04.051 · Cited by 723
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data
Brown, M. L., Riley, G. F., Schussler, N., & Etzioni, R. (2002) · Medical Care · doi:10.1097/00005650-200208001-00014 · Cited by 612
Racial/ethnic patterns of cancer in the United States, 1988-1992.
Miller, B.-A., Kolonel, L. N., Bernstein, L., Young, J. L., Swanson, G., West, D. W., Key, C., Liff, J. M., Glover, C. S., & Alexander, G. A. (1996) · Cited by 500
Tolley, D. A., Parmar, M. K. B., Grigor, K. M., Lallemand, G., & The Medical Research Council Superficial Bladder Cancer Working Party (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)66226-8 · Cited by 323
Denzinger, S., Burger, M., Walter, B., Knuechel, R., Roessler, W., Wieland, W. F., & Filbeck, T. (2007) · Urology · doi:10.1016/j.urology.2006.12.023 · Cited by 274
Cited by
Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., Kriegmair, M., Karl, A., Shen, Y., & Grossman, H. B. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.06.148 · Cited by 304
Self-citationAl‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018) · Medicine · doi:10.1097/md.0000000000011596 · Cited by 56
Sun, D., Hadjiiski, L., Bruno, G., Gormley, J., Chan, H.-P., Caoili, E. M., Cohan, R. H., Alva, A., Mihalcea, R., Zhou, C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27593-7 · Cited by 9
Metadata
- Authors
- Sievert, K. D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., & Stenzl, A.
- Venue
- World Journal of Urology
- Published
- 2009-03-07
- Volume
- 27
- Issue
- 3
- Pages
- 295-300
- ISSN
- 0724-4983 (ISSN-L)
- 1433-8726
- OpenAlex
- W2032659674
- Cited by
- 484
- References
- 25
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic aspects of bladder cancer: what are the benefits and costs? https://app.cochat.ai/papers/10.1007/s00345-009-0395-z
- The paper
- Sievert, K. D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., & Stenzl, A. (2009). Economic aspects of bladder cancer: what are the benefits and costs? World Journal of Urology. https://doi.org/10.1007/s00345-009-0395-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
